Full history for every metric is available with a Kvantra account
Zomedica Corp. (ZOM)
Key financial summary
Financials in USD| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | TTM | ||
|---|---|---|---|---|---|---|---|---|
| Total revenue | $m | 0 | 4 | 19 | 25 | 27 | 32 | 37 |
| Operating profit | $m | -84 | -21 | |||||
| Net profit | $m | -17 | -18 | -17 | -35 | -47 | -82 | -19 |
| EPS reported | $ | -0.08 | -0.02 | |||||
| Operating cashflow per share | $ | -0.02 | -0.01 | |||||
| Capex per share | $ | 0.00 | 0.00 | |||||
| FCF per share | $ | -0.02 | -0.01 | |||||
| Free cash flow | $m | -18 | -13 | |||||
| Net debt | $m | -53 | -44 | |||||
| Book value equity | $m | 115 | 107 | |||||
| Book value per share | $ | 0.12 | 0.11 | |||||
| Number of shares | m | 979.95 | 979.95 | |||||
| DPS (TTM paid) | $ | 0.00 | 0.00 |
Financial summary
Financials in USD| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | TTM | ||
|---|---|---|---|---|---|---|---|---|
| Value | ||||||||
| P/E TTM | x | - | - | |||||
| P/B LTM | x | 0.50 | 0.89 | |||||
| P/S LTM | x | 1.81 | 2.59 | |||||
| P/FCF LTM | x | -3.29 | -7.13 | |||||
| EV/EBITDA LTM | x | -0.59 | -4.42 | |||||
| EV/Sales LTM | x | 1.55 | 1.39 | |||||
| Earnings Yield LTM | % | -140.98% | -19.87% | |||||
| FCF Yield | % | -30.40% | -14.02% | |||||
| Quality | ||||||||
| ROE | % | -70.94% | -16.72% | |||||
| ROIC | % | -71.06% | -18.72% | |||||
| Operating margin | % | -263.36% | -56.28% | |||||
| Gross margin | % | 67.68% | 65.44% | |||||
| FCF/Sales | % | -55.10% | -36.25% | |||||
| Growth and momentum | ||||||||
| EPS Growth YoY | % | - | - | |||||
| Sales Growth YoY | % | +17.39% | +30.05% | |||||
| Net Income Growth YoY | % | - | - | |||||
| FCF Growth | % | - | - | |||||
| Operating Profit Growth | % | - | - | |||||
| Dividend and capital structure | ||||||||
| Dividend Yield | % | 0.00% | 0.00% | |||||
| Dividend Growth | % | 0.00% | 0.00% | |||||
| Payout Ratio | % | 0.00% | 0.00% | |||||
| FCF/Debt | x | -24.62 | -18.62 | |||||
| Net Debt/EBITDA | x | 0.10 | 0.56 | |||||
| EBIT/Net interest | x | 0.00 | 0.00 | |||||
| Net debt/market cap | % | -90.49% | -46.29% | |||||
| Net debt/Equity | x | -0.46 | -0.41 | |||||
| Gross debt/equity | x | 0.01 | 0.01 | |||||
Company overview
Zomedica Corp. is a veterinary healthcare enterprise dedicated to fulfilling the specific needs of clinical veterinarians through the creation of products for companion animals. The company is actively involved in the development and market introduction of its TRUFORMA platform, which delivers point-of-care diagnostic tools for various canine and feline illnesses. Additionally, Zomedica provides PulseVet, a system used to address a range of musculoskeletal conditions such as fractures, tendonitis, and torn ligaments in horses and smaller animals. Zomedica also maintains collaborative agreements, including one with Celsee, Inc. for the joint development and commercialization of liquid biopsy assays and consumables for detecting cancer in pets, and another with Seraph Biosciences, Inc. for the development and marketing of a novel pathogen detection system. Established in 2015 and based in Ann Arbor, Michigan, the company was formerly known as Zomedica Pharmaceuticals Corp. before adopting its current name in October 2020.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
Zomedica Corp. (ZOM)
Zomedica Corp. is a veterinary healthcare enterprise dedicated to fulfilling the specific needs of clinical veterinarians through the creation of products for companion animals. The company is actively involved in the development and market introduction of its TRUFORMA platform, which delivers point-of-care diagnostic tools for various canine and feline illnesses. Additionally, Zomedica provides PulseVet, a system used to address a range of musculoskeletal conditions such as fractures, tendonitis, and torn ligaments in horses and smaller animals. Zomedica also maintains collaborative agreements, including one with Celsee, Inc. for the joint development and commercialization of liquid biopsy assays and consumables for detecting cancer in pets, and another with Seraph Biosciences, Inc. for the development and marketing of a novel pathogen detection system. Established in 2015 and based in Ann Arbor, Michigan, the company was formerly known as Zomedica Pharmaceuticals Corp. before adopting its current name in October 2020.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free